New therapeutic targets in melanoma;Nuevas dianas terapéuticas en el melanoma

Actas Dermo-Sifiliograficas

Volumn 103, Issue 7, 2012, Pages 579-590

  Marti R M ^a   Sorolla, A ^a   Yeramian, A ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

Anti CTLA 4; BRAF; C kit; Melanoma; Molecular targets; Therapeutic targets

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; PREDICTION; TREATMENT RESPONSE;

EID: 84864701199     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2012.08.005     Document Type: Short Survey

References (112)

1. N. Ibrahim, and F.G. Haluska Molecular pathogenesis of cutaneous melanocytic neoplasms Annu Rev Pathol 4 2009 551 579
2. J. Lutzky New therapeutic options in the medical management of advanced melanoma Semin Cutan Med Surg 29 2010 249 257
3. F. Stegmeier, M. Warmuth, W.R. Sellers, and M. Dorsch Targeted cancer therapies in the twenty-first century: lessons from imatinib Clin Pharmacol Ther 87 2010 543 552
4. N.L. Spector, and K.L. Blackwell Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 27 2009 5838 5847
5. P.L. Myskowski, and A.C. Halpern Skin reactions to the new biologic anticancer drugs Curr Opin Support Palliat Care 3 2009 294 299
6. K.T. Flaherty New molecular targets in melanoma Curr Opin Oncol 16 2004 150 154 (Pubitemid 38402529)
7. F. Julia, L. Thomas, C. Dumontet, and S. Dalle Targeted therapies in metastatic melanoma: toward a clinical breakthrough Anticancer Agents Med Chem 10 2010 661 665
8. J.M. Ko, and D.E. Fisher A new era: melanoma genetics and therapeutics J Pathol 223 2011 241 250
9. L.A. Fecher, S.D. Cummings, M.J. Keefe, and R.M. Alani Toward a molecular classification of melanoma J Clin Oncol 25 2007 1606 1620 (Pubitemid 46733089)
10. J. Rother, and D. Jones Molecular markers of tumor progression in melanoma Current Genomics 10 2009 231 239
11. K.L. Nathanson Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma Biochem Pharmacol 80 2010 755 761
12. J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel, K.J. Busam, and H. Kutzner Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147 (Pubitemid 41653105)
13. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346 (Pubitemid 46630793)
14. M.A. Davies, and Y. Samuels Analysis of the genome to personalize therapy for melanoma Oncogene 29 2010 5545 5555
15. R. Botella-Estrada, and O. Sanmartín Jiménez Diferentes alteraciones genéticas causan diferentes melanomas y nuevas posibilidades terapéuticas Actas Dermosifiliogr 101 2010 394 400
16. A.Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, and U. Trefzer Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group J Clin Oncol 24 2006 4738 4745 (Pubitemid 46630937)
17. R.J. Sullivan, and M.B. Atkins Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond Expert Opin Investig Drugs 19 2010 1205 1216
18. C. Wellbrock, and A. Hurlstone BRAF as therapeutic target in melanoma Biochem Pharmacol 80 2010 561 567
19. G.S. Inamdar, S.V. Madhunapantula, and G.P. Robertson Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail Biochem Pharmacol 80 2010 624 637
20. C. Shepherd, I. Puzanov, and J.A. Sosman B-RAF inhibitors: an evolving role in the therapy of malignant melanoma Curr Oncol Rep 12 2010 146 152
21. W. Liu, J.W. Kelly, M. Trivett, W.K. Murray, J.P. Dowling, and R. Wolfe Distinct clinical and pathological features are associated with the BRAF (T1799A[V600E]) mutation in primary melanoma J Invest Dermatol 127 2007 900 905 (Pubitemid 46434654)
22. A. Viros, J. Fridlyand, J. Bauer, K. Lasithiotakis, C. Garbe, and D. Pinkel Improving melanoma classification by integrating genetic and morphologic features PLoS Med 5 2008 e120
23. B. Devitt, W. Liu, R. Salemi, R. Wolfe, J. Kelly, and C.Y. Tzen Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma Pigment Cell Melanoma Res 24 2011 666 672
24. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, and R.A. Smith Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 2006 835 844 (Pubitemid 44480537)
25. K.S. Smalley, M. Xiao, J. Villanueva, T.K. Nguyen, K.T. Flaherty, and R. Letrero CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations Oncogene 28 2009 85 94
26. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
27. D. Solit, and C.L. Sawyers Drug discovery: how melanomas bypass new therapy Nature 468 2010 902 903
28. I. Puzanov, and K.T. Flaherty Targeted molecular therapy in melanoma Semin Cutan Med Surg 29 2010 196 201
29. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
30. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, and L.A. Johnson COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
31. S.J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, and N. Dhomen Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
32. L.N. Kwong, and L. Chin The brothers RAF Cell 140 2010 180 182
33. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
34. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, and R. Alvarado RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
35. K. Cichowski, and P.A. Jänne Drug discovery: inhibitors that activate Nature 464 2010 358 359
36. C. Robert, J.P. Arnault, and C. Mateus RAF inhibition and induction of cutaneous squamous cell carcinoma Curr Opin Oncol 23 2011 177 182
37. H. Yoshida, T. Kunisada, T. Grimm, E.K. Nishimura, E. Nishioka, and S.I. Nishikawa Review: melanocyte migration and survival controlled by SCF/c-kit expression J Investig Dermatol Symp Proc 6 2001 1 5 (Pubitemid 33758596)
38. P.G. Natali, M.R. Nicotra, A.B. Winkler, R. Cavaliere, A. Bigotti, and A. Ullrich Progression of human cutaneous melanoma is associated with loss of expression of c-Kit proto-oncogene receptor Int J Cancer 52 1992 197 201
39. S.S. Shen, P.S. Zhang, O. Eton, and V.G. Prieto Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array J Cutan Pathol 30 2003 539 547 (Pubitemid 37255550)
40. R. Zakut, R. Perlis, S. Eliyahu, Y. Yarden, D. Givol, and S.D. Lyman KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells Oncogene 8 1993 2221 2229 (Pubitemid 23226956)
41. S. Huang, M. Luca, M. Gutman, D.J. McConkey, K.E. Langley, and S.D. Lyman AQ9 Enforced c-Kit expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential Oncogene 13 1996 2339 2347 (Pubitemid 27026017)
42. S. Ugurel, R. Hildenbrand, A. Zimpfer, P. La Rosée, P. Paschka, and A. Sucker Lack of clinical efficacy of imatinib in metastatic melanoma Br J Cancer 92 2005 1398 1405 (Pubitemid 40705006)
43. K. Wyman, M.B. Atkins, V. Prieto, O. Eton, D.F. McDermott, and F. Hubbard Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy Cancer 106 2006 2005 2011 (Pubitemid 43673217)
44. M.E. Mayorga, D. Sanchís, A.M. Pérez de Santos, A. Velasco, X. Dolcet, and J.M. Casanova Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines Melanoma Res 16 2006 127 135 (Pubitemid 44090045)
45. G. Lefevre, A.L. Glotin, A. Calipel, F. Mouriaux, T. Tran, and Z. Kherrouche Roles of stem cell factor/c-kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis J Biol Chem 279 2004 31769 31779 (Pubitemid 39037849)
46. O. Eton, L. Billings, K. Kim, M.L. Frazier, D.J. McConkey, and A.H. Diwan Bedikian phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM) J Clin Oncol 22 14S 2004 S7528
47. P.T. Went, S. Dirnhofer, M. Bundi, M. Mirlacher, P. Schraml, and S. Mangialaio Prevalence of KIT expression in human tumors J Clin Oncol 22 2004 4514 4520
48. C. Willmore-Payne, J.A. Holden, S. Tripp, and L.J. Layfield Human malignant melanoma: detection of BRAF and KIT activating mutations by high-resolution amplicon melting analysis Hum Pathol 36 2005 486 493 (Pubitemid 40776001)
49. J.C. Becker, E.B. Bröcker, D. Schadendorf, and S. Ugurel Imatinib in melanoma: a selective treatment option based on KIT mutation status? J Clin Oncol 25 2007 e9
50. K.B. Kim, O. Eton, D.W. Davis, M.L. Frazier, D.J. McConkey, and A.H. Diwan Phase II trial of imatinib mesylate in patients with metastatic melanoma Br J Cancer 99 2008 734 740
51. D. Handolias, A.L. Hamilton, R. Salemi, A. Tan, K. Moodie, and L. Kerr Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT Br J Cancer 102 2010 1219 1223
52. M.C. Garrido, and B.C. Bastian KIT as a therapeutic target in melanoma J Invest Dermatol 130 2010 20 27
53. S.E. Woodman, and M.A. Davies Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics Biochem Pharmacol 80 2010 568 574
54. P. Friedlander, and F.S. Hodi Advances in targeted therapy for melanoma Clin Adv Hematol Oncol 8 2010 619 635
55. F.S. Hodi, P. Friedlander, C.L. Corless, M.C. Heinrich, S. Mac Rae, and A. Kruse Major response to imatinib mesylate in KIT-mutated melanoma J Clin Oncol 26 2008 2046 2051
56. J. Lutzky, J. Bauer, and B.C. Bastian Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation Pigment Cell Melanoma Res 21 2008 492 493 (Pubitemid 351990966)
57. A. Quintás-Cardama, A.J. Lazar, S.E. Woodman, K. Kim, M. Ross, and P. Hwu Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib Nat Clin Pract Oncol 5 2008 737 740
58. S.E. Woodman, J.C. Trent, K. Stemke-Hale, A.J. Lazar, S. Pricl, and G.M. Pavan Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates Mol Cancer Ther 8 2009 2079 2085
59. D.E. Fisher, R. Barnhill, F.S. Hodi, M. Herlyn, G. Merlino, and E. Medrano Melanoma from bench to bedside: meeting report from the 6th international melanoma congress Pigment Cell Melanoma Res 23 2010 14 26
60. K.T. Flaherty, F.S. Hodi, and B.C. Bastian Mutation-driven drug development in melanoma Curr Opin Oncol 22 2010 178 183
61. H. Tawbi, and N. Nimmagadda Targeted therapy in melanoma Biologics 3 2009 475 484
62. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
63. J. Werzowa, S. Koehrer, S. Strommer, D. Cejka, T. Fuereder, and E. Zebedin Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo J Invest Dermatol 131 2011 495 503
64. M. López-Fauqued, R. Gil, J. Grueso, J. Hernández-Losa, A. Pujol, and T. Moliné The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells Int J Cancer 126 2010 1549 1561
65. H. Ludwig, D. Khayat, G. Giaccone, and T. Facon Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies Cancer 104 2005 1794 1807 (Pubitemid 41513161)
66. Y. Fernández, M. Verhaegen, T.P. Miller, J.L. Rush, P. Steiner, and A.W Opipari Jr. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications Cancer Res 65 2005 6294 6304 (Pubitemid 40994415)
67. J.Z. Qin, J. Ziffra, L. Stennett, B. Bodner, B.K. Bonish, and V. Chaturvedi Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells Cancer Res 65 2005 6282 6293 (Pubitemid 40994414)
68. A. Sorolla, A. Yeramian, X. Dolcet, A.M. Pérez de Santos, D. Llobet, and J.A. Schoenenberger Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines Br J Dermatol 158 2008 496 504 (Pubitemid 351239183)
69. S.N. Markowic, S.M. Geyer, F. Dawkins, W. Sharfman, M. Albertini, and W. Maples A phase II study of bortezomib in the treatment of metastatic malignant melanoma Cancer 103 2005 2584 2589 (Pubitemid 40800538)
70. Y. Su, K.I. Amiri, L.W. Horton, Y. Yu, G.D. Ayers, and E. Koehler A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets Clin Cancer Res 16 2010 348 357
71. A. Munshi, J.F. Kurland, T. Nishikawa, P.J. Chiao, M. Andreeff, and R.E. Meyn Inhibition of constitutively activated nuclear factor-kappa B radiosensitizes human melanoma cells Mol Cancer Ther 3 2004 985 992 (Pubitemid 39199593)
72. I. Mlynarczuk-Bialy, H. Roeckmann, U. Kuckelkorn, B. Schmidt, S. Umbreen, and J. Golab Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells Cancer Res 66 2006 7598 7605 (Pubitemid 44289216)
73. L.Y. Schumacher, D.D. Vo, H.J. Garban, B. Comin-Anduix, S.K. Owens, and V.B. Dissette Immunosensitization of tumour cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade) J Immunol 176 2006 4757 4765
74. C. Freudlsperger, A. Thies, U. Pfuller, and U. Schumacher The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells Anticancer Res 27 2007 207 213
75. G.B. Lesinski, K. Benninger, M. Kreiner, M. Quimper, G. Young, and W.E.3rd Carson Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells Cancer Immunol Immunother 58 2009 2031 2037
76. K. Amschler, M.P. Schön, N. Pletz, K. Wallbrecht, L. Erpenbeck, and M. Schön NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways J Invest Dermatol 30 2010 1073 1086
77. J.M. Seeger, P. Schmidt, K. Brinkmann, A.A. Hombach, O. Coutelle, and P. Zigrino The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack Cancer Res 70 2010 1825 1834
78. C. Wang, S. Li, and M.W. Wang Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition Toxicol In Vitro 24 2010 898 904
79. A. Yeramian, A. Sorolla, A. Velasco, M. Santacana, X. Dolcet, and J. Valls Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitises melanoma cells to Bortezomib by blocking Akt pathway Int J Cancer 2011 10.1002/ijc.26096 Epub ahead of print
80. L.R. Dick, and P.E. Fleming Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy Drug Discov Today 15 2010 243 249
81. A.A. Lane, and B.A. Chabner Histone deacetylase inhibitors in cancer therapy J Clin Oncol 27 2009 5459 5468
82. A.R. Jazirehi Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy Anticancer Drugs 21 2010 805 813
83. F. Facchetti, S. Previdi, M. Ballarini, S. Minucci, P. Perego, and C.A. La Porta Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors Apoptosis 9 2004 573 582 (Pubitemid 39158633)
84. J.J. Hwang, Y.S. Kim, M.J. Kim, S. Jang, J.H. Lee, and J. Choi A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways Anticancer Drugs 20 2009 815 821
85. S.N. Kang, E. Lee, M.K. Lee, and S.J. Lim Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma Drug Deliv 18 2011 143 149
86. J.H. Noh, J.H. Song, J.W. Eun, J.K. Kim, K.H. Jung, and H.J. Bae Systemic cell-cycle suppression by apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells Int J Mol Med 24 2009 205 226
87. A. Papi, A.M. Ferreri, P. Rocchi, F. Guerra, and M. Orlandi Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells Anticancer Res 30 2010 535 540
88. A. Munshi, T. Tanaka, M.L. Hobbs, S.L. Tucker, V.M. Richon, and R.E. Meyn Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci Mol Cancer Ther 5 2006 1967 1974 (Pubitemid 44336568)
89. T. Lillehammer, B.O. Engesaeter, L. Prasmickaite, G.M. Maelandsmo, O. Fodstad, and O. Engebraaten Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines J Gene Med 9 2007 440 451 (Pubitemid 46994573)
90. Y. Kato, B.C. Salumbides, X.F. Wang, D.Z. Qian, S. Williams, and Y. Wei Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma Mol Cancer Ther 6 2007 70 81 (Pubitemid 46206669)
91. D.D. Vo, R.M. Prins, J.L. Begley, T.R. Donahue, L.F. Morris, and K.W. Bruhn Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824 Cancer Res 69 2009 8693 8699
92. M. Nihal, C.T. Roelke, and G.S. Wood Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG) Pharm Res 27 2010 1103 1104
93. A. Hauschild, U. Trefzer, C. Garbe, K.C. Kaehler, S. Ugurel, and F. Kiecker Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma Melanoma Res 18 2008 274 278
94. A.I. Daud, J. Dawson, R.C. DeConti, E. Bicaku, D. Marchion, and S. Bastien Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial Clin Cancer Res 15 2009 2479 2487
95. P.N. Munster, D. Marchion, S. Thomas, M. Egorin, S. Minton, and G. Springett Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker Br J Cancer 101 2009 1044 1050
96. A. Rocca, S. Minucci, G. Tosti, D. Croci, F. Contegno, and M. Ballarini A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma Br J Cancer 100 2009 28 36
97. C. Abdullah, X. Xiaolei Wang, and D. Becker Molecular therapy for melanoma. Useful and not useful targets Cancer Biology & Therapy 10 2010 113 118
98. R.R. Braeuer, M. Zigler, G.J. Villares, A.S. Dobroff, and M. Bar-Eli Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment Semin Cancer Biol 21 2011 83 88
99. S. Kuphal, R. Bauer, and A-K. Bosserhoff Integrin signaling in malignant melanoma Cancer Metastasis Rev 24 2005 195 222 (Pubitemid 40922795)
100. R. Ria, A. Reale, A. Castrovilli, G. Mangialardi, F. Dammacco, and D. Ribatti Angiogenesis and progression in human melanoma Dermatol Res Pract 2010 2010 185687
101. K. Watson-Hurst, and D. Becker The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion Cancer Biol Ther 5 2006 1375 1382 (Pubitemid 44772267)
102. P. Hersey, J. Sosman, S. O'Day, J. Richards, A. Bedikian, and R. González A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + - dacarbazine in patients with stage IV metastatic melanoma Cancer 116 2010 1526 1534
103. G.M. Beasley, J.C. Riboh, C.K. Augustine, J.S. Zager, S.N. Hochwald, and S.R. Grobmyer Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma J Clin Oncol 29 2011 1210 1215
104. B. Basu, S. Biswas, J. Wrigley, B. Sirohi, and P. Corrie Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies Expert Rev Anticancer Ther 9 2009 1583 1598
105. S.J. O'Day, K.B. Kim, J.A. Sosman, A.C. Peterson, S. Feng, and D.R. Minor BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untrated advanced melanoma Eur J Cancer Suppl 7 2009 13
106. R.J. Kelly, and O. Rixe Axitinib (AG-013736) Recent Results Cancer Res 184 2010 33 44
107. P. Boasberg, O. Hamid, and S. O'Day Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade Semin Oncol 37 2010 440 449
108. J.D. Wolchok, A. Hoos, S. O'Day, J.S. Weber, O. Hamid, and C. Lebbé Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
109. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
110. N. Halama, I. Zoernig, and D. Jaeger Advanced malignant melanoma: immunologic and multimodal therapeutic strategies J Oncol 2010 2010 1 8
111. M. Martínez-Alonso, N. Llecha, M.E. Mayorga, A. Sorolla, X. Dolcet, and V. Sanmartín Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation J Int Med Res 37 2009 1813 1822
112. T.L. Hocker, M.K. Singh, and H. Tsao Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside J Invest Dermatol 128 2008 2575 2595